NCI, NCRI and EORTC working group outline risk-assessment approach for biomarker-driven cancer clinical trials
29 Apr 2014
In an article published in The Lancet Oncology, an NCI (US National Cancer Institute), NCRI (UK National Cancer Research Institute), and EORTC (European Organisation for Research and Treatment of Cancer) working group outline a practical risk-management approach for effective integration of biomarkers into cancer clinical trials. Their work provides the international community with a set of common principles by which biomarkers can be integrated into clinical trials, exchange of data can be facilitated, quality promoted, and research accelerated while simultaneously respecting local approaches and legislation.
Their risk-assessment approach for designing and conducting cancer clinical trials include risks to patient safety, operational risks, and biomarker development risks, and for each risk they evaluate possible consequences, provide solutions along with examples of these as well as references to helpful resources. Concerning protocol design, the working group recommends items that a protocol should include as well as items that should be assessed during protocol development. For the conduct of the trial, they make recommendations for the close monitoring of variability in test results, and they also make recommendations for particular aspects following completion of the trial.
Dr. Jacqueline Hall, who coordinated this NCI, NCRI, and EORTC working group says, “We readily acknowledge that in today’s clinical trial landscape, many stakeholders play a role in clinical trials. These include regulators, public authorities, and patients, amongst others. By opening this discussion to others, we hope to find solutions to the varied challenges facing molecularly driven clinical research.”
Support for this research came from the EORTC Charitable Trust and the UK Department of Health’s National Institute for Health Research Biomedical Research Centres funding scheme.
For more information please contact: www.eortc.org/contact
John Bean, PhD
EORTC, Medical Science Writer
Related News
World Cancer Day: How clinical cancer research changes lives
4 Feb 2026
New international study shows access to patient-reported outcome data improves the consistency of the evaluation of cancer treatment adverse events
27 Jan 2026
First Site Activated and First Patient Randomised in new brain cancer study VIGOR – EORTC‑2427‑BTG
26 Jan 2026
EORTC and EMA, jointly with international stakeholders, have published a multistakeholder roadmap to accelerate treatment optimisation in oncology
16 Jan 2026
New EORTC quality of life questionnaire for adolescents and young adults with cancer
8 Jan 2026
P-Value Workshop
19 Dec 2025
EORTC participation at ISPOR Europe 2025 conference
7 Nov 2025
EORTC Quality of Life Group participating at the ISOQOL 2025 Conference
22 Oct 2025
New results and forthcoming trials presented at ESMO 2025 underline EORTC’s commitment to patient-centred research
21 Oct 2025
EORTC celebrates the 100th anniversary of p-value on World Statistics Day
20 Oct 2025
